Fluoroquinolonas
Autor(a) principal: | |
---|---|
Data de Publicação: | 1994 |
Outros Autores: | |
Tipo de documento: | Artigo |
Idioma: | por |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | https://revista.spmi.pt/index.php/rpmi/article/view/2471 |
Resumo: | Fluoroquinolones are synthetic compounds, structurally related to nalidixic acid. Its mechanism of action involves inhibition of bacterial DNA girase. They have a broad spectrum of activity. They are highly active against Enterobacteriaceae and also active against some strains of Pseudomonas aeruginosa and Staphilococcus sp., however recent reports indicate increasing resistance. They have poor activity against streptococci and anaerobes. These agents exhibited excelknt oral absorption, good tissue distribution and are excreted primarily by way of the kidney. The incidence of adverse effects to fluoroquinolones appears to be low. The most common are gastrointesti nal reactions, followed by central nervous system disorders. Hypersensivity reactions occur occasionally. Fluoroquinolones interact with a number of other agents, with potential clinicai manifestations, such as antacids, theophylline, warf arine. The bioavailability after oral administration allows the use of these agents without loss of efficacity, when compared with IV administration, thus reducing substantially the treatment cost. |
id |
RCAP_65b88cd44f9c92a09e04ad31941f326b |
---|---|
oai_identifier_str |
oai:oai.revista.spmi.pt:article/2471 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
FluoroquinolonasfluoroquinolonasantimicrobianosnorfloxacinaciprofloxacinaofloxacinapefloxacinafluoroquinolonesantimicrobialsnorfloxacinofloxacinpefloxacinciprofloxacinFluoroquinolones are synthetic compounds, structurally related to nalidixic acid. Its mechanism of action involves inhibition of bacterial DNA girase. They have a broad spectrum of activity. They are highly active against Enterobacteriaceae and also active against some strains of Pseudomonas aeruginosa and Staphilococcus sp., however recent reports indicate increasing resistance. They have poor activity against streptococci and anaerobes. These agents exhibited excelknt oral absorption, good tissue distribution and are excreted primarily by way of the kidney. The incidence of adverse effects to fluoroquinolones appears to be low. The most common are gastrointesti nal reactions, followed by central nervous system disorders. Hypersensivity reactions occur occasionally. Fluoroquinolones interact with a number of other agents, with potential clinicai manifestations, such as antacids, theophylline, warf arine. The bioavailability after oral administration allows the use of these agents without loss of efficacity, when compared with IV administration, thus reducing substantially the treatment cost.As fluoroquinolonas são compostos sintéticos quimicamente relacionados com o ácido nalidíxico. Embora não estando ainda bem esclarecido o mecanismo de acção, pensa-se que actuam inibindo a DNA-girase. São agentes antimicrobianos de largo espectro, possuindo elevada actividade contra Enterobacteriáceas. São activas contra algumas estirpes de Pseudomonas aeruginosa e Estafilococus sp.,contudo bibliografia recente refere aumento de resistências. Tem actividade reduzida contra Streptococcus e anaeróbios. São bem absorvidas por via oral, apresentando uma boa distribuição tecidular, excretando-se preferencialmente por via renal. São fármacos seguros com poucos efeitos secundários, sendo os mais frequentes os gastrointestinais, algumas alterações a nível do S.N.C. e mais raramente reacções de hipersensibilidade. As interacções com alguns medicamentos nomeadamente antiácidos, teofilina e varfarina podem ter algum significado clínico. A biodisponibilidade das fluoroquinolonas permite a sua administração por via oral sem perda de eficácia terapêutica, quando comparadas com administração IV, reduzindo assim substancialmente os custos de tratamento.Sociedade Portuguesa de Medicina Interna1994-09-30info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttps://revista.spmi.pt/index.php/rpmi/article/view/2471Internal Medicine; Vol. 1 No. 3 (1994): Julho/ Setembro; 189-192Medicina Interna; Vol. 1 N.º 3 (1994): Julho/ Setembro; 189-1922183-99800872-671Xreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAPporhttps://revista.spmi.pt/index.php/rpmi/article/view/2471https://revista.spmi.pt/index.php/rpmi/article/view/2471/1816Direitos de Autor (c) 1994 Medicina Internainfo:eu-repo/semantics/openAccessMorais Almeida, Maria da GraçaMachado, Maria José2023-10-07T06:21:45Zoai:oai.revista.spmi.pt:article/2471Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T20:33:40.753842Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
Fluoroquinolonas |
title |
Fluoroquinolonas |
spellingShingle |
Fluoroquinolonas Morais Almeida, Maria da Graça fluoroquinolonas antimicrobianos norfloxacina ciprofloxacina ofloxacina pefloxacina fluoroquinolones antimicrobials norfloxacin ofloxacin pefloxacin ciprofloxacin |
title_short |
Fluoroquinolonas |
title_full |
Fluoroquinolonas |
title_fullStr |
Fluoroquinolonas |
title_full_unstemmed |
Fluoroquinolonas |
title_sort |
Fluoroquinolonas |
author |
Morais Almeida, Maria da Graça |
author_facet |
Morais Almeida, Maria da Graça Machado, Maria José |
author_role |
author |
author2 |
Machado, Maria José |
author2_role |
author |
dc.contributor.author.fl_str_mv |
Morais Almeida, Maria da Graça Machado, Maria José |
dc.subject.por.fl_str_mv |
fluoroquinolonas antimicrobianos norfloxacina ciprofloxacina ofloxacina pefloxacina fluoroquinolones antimicrobials norfloxacin ofloxacin pefloxacin ciprofloxacin |
topic |
fluoroquinolonas antimicrobianos norfloxacina ciprofloxacina ofloxacina pefloxacina fluoroquinolones antimicrobials norfloxacin ofloxacin pefloxacin ciprofloxacin |
description |
Fluoroquinolones are synthetic compounds, structurally related to nalidixic acid. Its mechanism of action involves inhibition of bacterial DNA girase. They have a broad spectrum of activity. They are highly active against Enterobacteriaceae and also active against some strains of Pseudomonas aeruginosa and Staphilococcus sp., however recent reports indicate increasing resistance. They have poor activity against streptococci and anaerobes. These agents exhibited excelknt oral absorption, good tissue distribution and are excreted primarily by way of the kidney. The incidence of adverse effects to fluoroquinolones appears to be low. The most common are gastrointesti nal reactions, followed by central nervous system disorders. Hypersensivity reactions occur occasionally. Fluoroquinolones interact with a number of other agents, with potential clinicai manifestations, such as antacids, theophylline, warf arine. The bioavailability after oral administration allows the use of these agents without loss of efficacity, when compared with IV administration, thus reducing substantially the treatment cost. |
publishDate |
1994 |
dc.date.none.fl_str_mv |
1994-09-30 |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://revista.spmi.pt/index.php/rpmi/article/view/2471 |
url |
https://revista.spmi.pt/index.php/rpmi/article/view/2471 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.relation.none.fl_str_mv |
https://revista.spmi.pt/index.php/rpmi/article/view/2471 https://revista.spmi.pt/index.php/rpmi/article/view/2471/1816 |
dc.rights.driver.fl_str_mv |
Direitos de Autor (c) 1994 Medicina Interna info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
Direitos de Autor (c) 1994 Medicina Interna |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Sociedade Portuguesa de Medicina Interna |
publisher.none.fl_str_mv |
Sociedade Portuguesa de Medicina Interna |
dc.source.none.fl_str_mv |
Internal Medicine; Vol. 1 No. 3 (1994): Julho/ Setembro; 189-192 Medicina Interna; Vol. 1 N.º 3 (1994): Julho/ Setembro; 189-192 2183-9980 0872-671X reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1817550902168387584 |